|Articles|February 1, 1996

February 1996
Volume 2
Issue 2

Quantitative and Cost Evaluation of Three Antiglaucoma Beta-Blocker Agents: Timoptic-XE7 versus Two Generic Levobunolol Products

Author(s)David Hartenbaum, MD, Michael Stek, MD, Brian Haggert, MS

Download PDF: Quantitative and Cost Evaluation of Three Antiglaucoma Beta-Blocker Agents: Timoptic-XE7 versus Two Generic Levobunolol Products

Articles in this issue

over 30 years ago

Article

Adapting Pharmacy Services to the Needs of Managed Care

over 30 years ago

Article

Risk-Adjusted Physician and Hospital Profiling: The Keys to Managed Care Success

over 30 years ago

Article

Correspondence regarding, "Partial Medication Compliance: The Enigma in Poor Medical Outcomes"

over 30 years ago

Article

Advanced Practice Nurses and Success of Organized Delivery Systems

over 30 years ago

Article

Pharmacoeconomic Impact of Injectable Sumatriptan on Migraine-Associated Healthcare Costs

over 30 years ago

Article

Estimated Costs of Treating Stress Urinary Incontinence in Elderly Women According to the AHCPR Clinical Practice Guidelines

over 30 years ago

Article

Ethical Issues in Managed Care

over 30 years ago

Article

The Economics of Compliance in Managed Healthcare Settings

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

ByThomas W. Martens, MD,Bimal V. Patel, PharmD, MS,Sharon M. Wang, PharmD, MS,Laurel H. Messer, PhD, MPH, RN, CDCES, BC-ADM,Jordan E. Pinsker, MD,Daniel C. Malone, PhD, RPh,Miranda R. Polin, MS, BS,Diana I. Brixner, PhD, RPh,Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES,Osagie Ebekozien, MD, MPH

July 23rd 2026

Geographical Access to Preferred Pharmacies in Medicare Part D

ByPinka Chatterji, PhD,Yiran Han, PhD,Chun-Yu Ho, PhD

July 22nd 2026

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

ByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MA

July 16th 2026

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

Quantitative and Cost Evaluation of Three Antiglaucoma Beta-Blocker Agents: Timoptic-XE7 versus Two Generic Levobunolol Products

Articles in this issue

Related Content

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

Geographical Access to Preferred Pharmacies in Medicare Part D

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Trending on AJMC

Jeff Hunnicutt to Bring Community Oncology Roots to New Role as Navista COO

Semaglutide More Than Doubled Likelihood of MASH Resolution

Once-Daily Pill Zasocitinib Clears Psoriasis at Toughest Sites

Contributor: How Health Systems Can Rebalance Behavioral Health Access

GLP-1 Receptor Agonists Linked to Lower Fracture Risk in T2D